作者: R. Buhl , D. Price
DOI: 10.1111/J.1368-504X.2004.00262.X
关键词:
摘要: Summary Asthma can place considerable restrictions on the health-related quality of life asthma patients and their families; this burden may be greatest when symptoms are not adequately controlled. The Symbicort® Adjustable Maintenance Dosing Programme, consisting studies from several different countries, compared a guided self-management plan that allows adjustable maintenance dosing using budesonide/formoterol in single inhaler (Symbicort) with fixed dosing. Quality was assessed three asthma-specific generic questionnaires. Clinically relevant improvements mean scores were observed beginning to end 1-month run-in, which maintained or further improved during randomised treatment both groups. A modified patient enablement instrument also used UK study assess patients' feelings control towards asthma. showed significantly (p < 0.05) greater These outcomes achieved less drug usage,